Wellington Management Group LLP Sells 7,787 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Wellington Management Group LLP decreased its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 12.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 57,370 shares of the biopharmaceutical company's stock after selling 7,787 shares during the period. Wellington Management Group LLP's holdings in Halozyme Therapeutics were worth $2,743,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Halozyme Therapeutics by 3.0% in the fourth quarter. Vanguard Group Inc. now owns 13,281,714 shares of the biopharmaceutical company's stock valued at $634,999,000 after buying an additional 386,618 shares during the period. Geode Capital Management LLC grew its holdings in shares of Halozyme Therapeutics by 1.0% during the 3rd quarter. Geode Capital Management LLC now owns 3,060,131 shares of the biopharmaceutical company's stock worth $175,194,000 after purchasing an additional 30,901 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Halozyme Therapeutics by 0.6% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,783,177 shares of the biopharmaceutical company's stock valued at $85,254,000 after purchasing an additional 9,780 shares in the last quarter. Norges Bank bought a new position in Halozyme Therapeutics in the fourth quarter worth $60,054,000. Finally, Arrowstreet Capital Limited Partnership increased its holdings in Halozyme Therapeutics by 141.3% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 992,887 shares of the biopharmaceutical company's stock valued at $47,470,000 after buying an additional 581,475 shares during the period. 97.79% of the stock is currently owned by institutional investors.

Remove Ads

Wall Street Analyst Weigh In

Several analysts have recently weighed in on HALO shares. Piper Sandler lifted their target price on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Benchmark reissued a "buy" rating and issued a $75.00 target price on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright reaffirmed a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Finally, Wells Fargo & Company dropped their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, Halozyme Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus target price of $62.78.

Insider Activity at Halozyme Therapeutics

In related news, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now directly owns 173,756 shares in the company, valued at $10,126,499.68. This trade represents a 0.97 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Jeffrey William Henderson sold 5,000 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The shares were sold at an average price of $56.30, for a total transaction of $281,500.00. Following the completion of the sale, the director now directly owns 38,611 shares of the company's stock, valued at $2,173,799.30. The trade was a 11.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 22,200 shares of company stock worth $1,286,568 over the last ninety days. Company insiders own 2.40% of the company's stock.

Halozyme Therapeutics Trading Down 5.5 %

HALO traded down $3.39 during mid-day trading on Wednesday, reaching $57.89. The stock had a trading volume of 988,264 shares, compared to its average volume of 1,412,926. The stock has a market capitalization of $7.15 billion, a P/E ratio of 16.88, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 52 week low of $37.73 and a 52 week high of $66.00. The company has a debt-to-equity ratio of 4.14, a quick ratio of 9.15 and a current ratio of 7.80. The firm's fifty day simple moving average is $60.36 and its two-hundred day simple moving average is $54.99.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The firm had revenue of $298.01 million during the quarter, compared to analysts' expectations of $285.74 million. On average, equities analysts predict that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.